

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and
Waiver under 18 U.S.C. § 208(b)(3)

Wayne K. Goodman, M.D.

Committee: Psychopharmacologic Drugs Advisory Committee

Meeting Date: March 23, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to new drug application (NDA) 20-717/S-019, Provigil (modafinil tablets), sponsored by Cephalon, Inc., for the proposed indication for the treatment of attention deficit hyperactivity disorder (ADHD), I am eligible to receive a waiver under 18 U.S.C. § 208(b)(3).

Type of Interest	Nature	Magnitude
Employer's Related Contracts/Grants	Competitor	Between \$100,001 and \$300,000 per year.
Employer's Related Contract/Grant	Competitor	Less than \$100,000 per year.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waiver is not valid.

_____/s/
Signature of SGE

Date